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Abstract
Background The ‘placebo effect’ and ‘nocebo effect’ are phenomena whereby beneﬁcial (placebo) or adverse (nocebo) ef-
fects result from the expectation that an inert substance will relieve or cause a particular symptom. These terms are often
inappropriately applied to effects experienced on drug therapy. Quantifying the magnitude of placebo and nocebo effects
in clinical trials is problematic because it requires a ‘no treatment’ arm. To overcome the difﬁculties associated with measuring
the nocebo effect, and the fact that its deﬁnition refers to inert compounds, rather than drugs, we introduce the concept of
‘drucebo’ (a combination of DRUg and plaCEBO or noCEBO) to relate to beneﬁcial or adverse effects of a drug, which result
from expectation and are not pharmacologically caused by the drug. As an initial application of the concept, we have esti-
mated the contribution of the drucebo effect to statin discontinuation and statin-induced muscle symptoms by performing
a systematic review of randomized controlled trial of statin therapy.
Methods This preferred reporting items for systematic reviews and meta-analysis-compliant systematic review was prospec-
tively registered in PROSPERO (CRD42017082700). We searched PubMed and Cochrane Central from inception until 3 January
2018 using a search strategy designed to detect studies including the concepts (Statins AND Placebo AND muscle pain). We
included studies that allowed us to quantify the drucebo effect for adverse muscle symptoms of statins by (i) comparing re-
ported rates of muscle symptoms in blinded and unblinded phases of randomized controlled trials and (ii) comparing rates of
muscle symptoms at baseline and during blinded therapy in trials that included patients with objectively conﬁrmed statin in-
tolerance at baseline. Extraction was performed by two researchers with disagreements settled by a third reviewer.
Results Five studies allowed the estimation of the drucebo effect. All trials demonstrated an excess of side effects under open-
label conditions. The contribution of the drucebo effect to statin-associated muscle pain ranged between 38% and 78%. The het-
erogeneity of study methods, outcomes, and reporting did not allow for quantitative synthesis (meta-analysis) of the results.
Conclusions The drucebo effect may be useful in evaluating the safety and efﬁcacy of medicines. Diagnosis of the drucebo
effect in patients presenting with statin intolerance will allow restoration of life-prolonging lipid-lowering therapy. Our study
was limited by heterogeneity of included studies and lack of access to individual patient data. Further studies are necessary to
better understand risk factors for and clinical management of the drucebo effect.
Keywords Statins; Nocebo; Placebo; Drucebo
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Introduction
The Latin word ‘placebo’ translates as ‘I will please’, whereas
‘nocebo’ means ‘I will harm’.1 The ‘placebo effect’ and
‘nocebo effect’ are the phenomena whereby beneﬁcial (pla-
cebo) or adverse (nocebo) effects result from the expectation
that an inert substance will relieve or cause a particular
symptom (Table 1). Beneﬁts (placebo) and harms (nocebo)
associated with inert therapies are usually subjective2 and
are associated with complex neurobiological and psychologi-
cal mechanisms.
3
The concept of ‘placebo effect’ is also com-
monly used in the context of therapeutic drugs, relating to an
effect of a drug (rather than an inert substance) resulting
from expectation of such an effect. The concept of ‘nocebo’
effect is increasingly being used in the same context and
means the appearance of the drug-related symptoms while
treating with the given drug, which are not associated with
the medicine but with expectations (fear) and knowledge of
these possible adverse effects.
Reduction of endogenous cholesterol synthesis by compet-
itive inhibitors of HMG-CoA-reductase (statins) is safe and ef-
fective in the primary and secondary prevention of
cardiovascular (CV) disease (CVD).4 While statin therapy is
generally well-tolerated, it has been associated with some
adverse effects,5 including muscle-related symptoms (statin-
associated muscle symptoms, SAMS).
6
In fact, causality has
been conﬁrmed only for three statin-related adverse effects
—SAMS, new onset diabetes, and temporary elevations of al-
anine aminotransferase activity.
7
Statin-associated adverse
effects are sometimes sufﬁciently severe to lead to treatment
discontinuation.8–10 The phenomenon of ‘statin intolerance’
and associated dose reduction or cessation has been shown
to be associated with increased risk of myocardial infarction
and coronary heart disease11 and a composite outcome of
myocardial infarction, stroke, or death.
12
Given the millions
of statin users, worldwide, even a small prevalence of statin
discontinuation would render a huge number of patients at
risk of CV events.
Statin-associated muscle symptoms provide an interesting
context for the study of adverse effects resulting from the ex-
pectation that such effects will occur. The measurement of
the severity of muscle pain is subjective, and muscle pain of
unrelated origin may be misattributed to statin therapy. Pa-
tients may expect harm with treatment with a drug because
of the adverse effects listed in patient (or study participant)
information leaﬂets.13 However, expectations of harm from
statins may be greater than for other drugs because of the
widespread reporting of adverse effects of statins
Table 1 Deﬁnitions of terms
Term Deﬁnition Method of estimation/quantiﬁcation
Placebo effect Beneﬁt experienced by patient taking
an inert substance as a result of
expectation of beneﬁt
Continuous outcome:
(Symptom improvement
in non-active treatment group) –
(Symptom improvement in
no-treatment group)
Categorical Outcome:
HR/OR/RR(beneﬁt)non-active treatment –
HR/OR/RR (beneﬁt)no treatment
Nocebo effect Harm experienced by patient taking
an inert substance as a result of
expectation of harm
Continuous outcome:
(Adverse effects in non-active
treatment group) – (Adverse effects
in no-treatment group)
Categorical outcome:
HR/OR/RR(harm)non-active treatment –
HR/OR/RR(harm)no treatment
Positive drucebo effect Beneﬁt experienced by patient
taking a drug that is not
attributable to the pharmacological
action of the drug
Continuous outcome:
(Symptom improvement
in drug treatment group
under open-label conditions) –
(Symptom improvement in
drug treatment group
under blinded conditions)
(Continues)
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(particularly relating to muscle pain, cogitative dysfunction,
and new onset diabetes) in the lay press, in what has been
described as a cult of ‘statin fear’.14
A systematic and rigorous approach to measuring symp-
tom severity and understanding causality is required in order
to conﬁrm that adverse effects are truly a result of statins
and therefore to prevent the unnecessary cessation of a ben-
eﬁcial therapy. Deﬁnitions of SAMS have been proposed by
the American College of Cardiology and the American Heart
Association,
15
a Canadian Working Group
16
and the National
Lipid Association who proposed a score, which has been re-
cently updated, to ascertain the likelihood that muscle symp-
toms were caused by statin therapy, based upon the regional
distribution of the pain, the temporal pattern, symptom res-
olution with dechallenge, and symptom recurrence with re-
currence of statin therapy.8,17 An international panel of
experts (International Lipid Expert Panel) have developed a
uniﬁed deﬁnition of statin intolerance that includes require-
ments for the inability to tolerate at least two different
statins at low dose, intolerance associated with biomarker
abnormalities, which improves upon dose decrease or discon-
tinuation, and the exclusion of predisposing factors such as
drug–drug interactions.18,19
Reported incidence of muscle symptoms attributable
to statins are consistently lower in randomized placebo-
controlled trials (3–5%) than in observational studies
(15–20%) and data collected in non-blinded means.
Summarizing data from observational studies, Tobert and
Newman estimated that 5% of patients were reported
to be intolerant of statins owing to muscle symptoms,
although such effects are rarely accompanied by changes
in biomarkers such as creatine kinase, which would be ex-
pected to be associated with muscle damage.2 Hence,
however rigorously pain is measured, there exists a large
element of subjectivity in its quantiﬁcation. In the context
of an observational study where the allocated treatment and
its side effects are known to the participant, this subjectivity
may lead to increased reporting of adverse effects. However,
the differences between randomized controlled trials (RCTs)
and observational studies could be explained in part by differ-
ent patient characteristics because of more rigorous
inclusion/exclusion criteria in RCTs.
In RCTs, the incidence of muscle symptoms is similar in
participants treated with statins and those assigned to the
placebo group.20,21 A meta-analysis including 83 880 partici-
pants in 29 primary and secondary prevention RCTs found
no evidence of a difference in reported muscle symptoms
between statin and placebo groups.
22
The authors of the
meta-analysis raised the possibility of the ‘nocebo effect’
being responsible for the high rate of reporting of muscle
symptoms in non-blinded trials.
22
These ﬁndings were
conﬁrmed in a more recent meta-analysis.23
Evidence relating to the role of the nocebo effect in
statin intolerance was recently extensively reviewed by
Tobert and Newman.2 Since then, Gupta et al., in a retro-
spective analysis of the Anglo-Scandinavian Cardiac Out-
comes Trial, found no difference between the incidence
of muscle symptoms in patients taking atorvastatin 10 mg
compared with placebo [hazard ratio 1.03, 95% conﬁdence
interval (CI) 0.88–1.21] in the initial double-blind phase of
the trial, whereas in a later-open-label extension, signiﬁ-
cantly more muscle symptoms were reported in the
statin-treated group 1.41 (1.10–1.79).24 These results were
strongly suggestive of the reporting of adverse effects,
which were not caused by the pharmacological actions of
the drug—and were attributed to the nocebo effect by
the authors.24
However, it is questionable whether these differences truly
represent the nocebo effect. Rojas-Mirquez has highlighted
the difﬁculties with measuring a true nocebo effect. In particu-
lar, they observe that ‘In the context of a RCT, in order to assess
a true placebo or nocebo effect, the non-active drug should ide-
ally be compared to a no-treatment group. True placebo re-
sponse would be symptom improvements in the non-active
treatment arm that go above and beyond spontaneous remis-
sion in the no-treatment group. Likewise, true nocebo
Table 1 (continued)
Term Deﬁnition Method of estimation/quantiﬁcation
Categorical outcome:
HR/OR/RR(beneﬁt)drug (open label) –
HR/OR/RR (beneﬁt)drug (blind)
Negative drucebo effect Harm experienced by patient
taking a drug that is not
attributable to the
pharmacological
action of the drug
Continuous outcome:
(Adverse effects in drug
treatment group under open-label
conditions) – (Adverse effects in
drug treatment group under
blinded conditions)
Categorical outcome:
HR/OR/RR(harm)drug (open label) –
HR/OR/RR (harm)drug (blind)
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responses are adverse effects that go above and beyond
symptoms in the no-treatment group’.25While a similar degree
of adverse effects in a treatment and placebo group can give
reassurance that adverse effects are not drug-related, it cannot
estimate the extent to which expectation of an adverse effect is
responsible for the patient experiencing the effect. The Nordic
Cochrane Centre reviewed studies in all conditions, which
compared placebo with no treatment and found no evidence
for clinically important effects of placebo.26
To overcome the difﬁculties associated with measuring the
nocebo effect, and the fact that its deﬁnition refers to inert
compounds, rather than drugs, we introduce the concept of
‘drucebo’ (a combination of DRUg and plaCEBO or noCEBO)
to relate to beneﬁcial or adverse effects of a drug, which re-
sult from expectation and are not pharmacologically caused
by the drug (Table 1). Our portmanteau term may not imme-
diately appeal to classicists, but we anticipate it will prove to
be a useful concept with wide applicability across all medical
disciplines. We aim to estimate the magnitude of the
negative drucebo effect in the speciﬁc context of statin
therapy by (i) comparing reported rates of muscle symptoms
in blinded and unblinded phases of a RCT and (ii) comparing
rates of muscle symptoms at baseline and during blinded
therapy during a placebo-controlled trial that included
patients with statin intolerance at baseline.
Methods
Data sources and searches
We followed the guidelines of the 2009 preferred reporting
items for systematic reviews and meta-analysis statement.27
The study protocol was prospectively registered in the PROS-
PERO database (Ref: CRD42017082700). Because this study
was planned as a meta-analysis of data available in the public
domain, neither ethical approval nor patient informed consent
were needed. PubMed (Medline) AND Cochrane Central were
searched from inception until 3 January 2018 using the
following search terms: (‘atorvastatin’ OR ‘simvastatin’ OR
‘rosuvastatin’ OR ‘ﬂuvastatin’ OR ‘pravastatin’ OR ‘pitavastatin’
OR ‘lovastatin’ OR ‘cerivastatin’ OR ‘statin therapy’ OR statin*
OR ‘hydroxymethylglutaryl-CoA reductase inhibitors’) AND
(blinded OR masked OR placebo OR nocebo) AND (muscle
OR myopathy OR myalgia OR statin-related/associated side
effects statin-related/associated adverse effects OR SAMS).
The wild-card term ‘*’ was used to increase the sensitivity of
the search strategy.
Study selection
Randomized controlled trials were eligible for inclusion if
they compared statin therapy with placebo and either
included an open-label phase and a blinded phase or re-
cruited participants with prior statin intolerance due to mus-
cle symptoms, objectively conﬁrmed through cessation and
rechallenge with daily statin therapy. No language criteria
were applied.
Data extraction
Data were extracted into a pre-prepared form. This was car-
ried out independently by two reviewers (P. E. P. + M. B.).
Discrepancies were resolved by consensus, or discussion with
a third reviewer (D. P. M.). Extracted information included
ﬁrst author, year of publication, citation, study design;
number of participants (divided into experimental groups
where appropriate; age, gender, and body mass index of the
participants; baseline systolic and diastolic blood pressures;
baseline total cholesterol, high density lipoprotein choles-
terol, low density lipoprotein cholesterol, triglycerides, and
history of SAMS.
Quality assessment
Assessment of risk of bias in the studies included in the anal-
ysis was performed systematically using the Cochrane revised
quality assessment tool for RCTs (RoB 2.0) based upon the
blinded phase of the studies.28 The Cochrane tool has ﬁve
criteria for quality assessment: (i) Bias arising from the ran-
domization process; (ii) Bias due to deviations from intended
interventions; (iii) Bias due to missing outcome data; (iv) Bias
in measurement of the outcome; (v) Bias in selection of the
reported result. The risk of bias in each study was judged to
be either low risk of bias, some concerns or high risk of bias.
Risk of bias assessment was performed independently by two
reviewers (P. E. P. and M. B.); disagreements were resolved
by a third reviewer (D. P. M.).
Data synthesis and analysis
Owing to the small number of studies found and the hetero-
geneity of methods used, we did not perform quantitative
data synthesis (meta-analysis) but instead produced a narra-
tive synthesis of the results.
Role of the funding source
This work was not externally funded and no funding organiza-
tion had any involvement.
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Results
Search results and trial ﬂow
After automated removal of duplicates by Endnote, 934 pub-
lications were identiﬁed for screening. After screening of ti-
tles and abstracts, 14 papers were selected for full-text
screening. Five papers were rejected as duplicate reports,
one paper was rejected for not including an appropriate pla-
cebo arm, one paper was rejected for not including a statin,
one paper was rejected for an inappropriate (weekly) statin
dose, and one paper was rejected for not reporting an appro-
priate endpoint. This left ﬁve studies for inclusion (Table 2),
and these are described in the succeeding text. The quality
assessment of the included studies is presented in Table 3.
Eligible studies
Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering
arm
The lipid-lowering arm of the Anglo-Scandinavian Cardiac
Outcomes Trial was a large double-blind RCT comparing
atorvastatin 10 mg and placebo, which was conducted be-
tween 1998 and 2002.29 The trial was stopped early for efﬁ-
cacy, and patients were unblinded and offered the
opportunity to be treated with open-label statins. Both
statin users and non-users were followed up for adverse ef-
fects and CV events, and the two groups were generally well
matched with respect to baseline characteristics. This unique
set of circumstances allowed the largest investigation
(10 180 participants) to date of the difference between ad-
verse effects of statins under blinded and open-label condi-
tions. As already mentioned earlier, the authors found no
difference between the incidence of muscle symptoms in pa-
tients taking atorvastatin 10 mg compared with placebo—
hazard ratio (95% CI) 1.03 (0.88–1.21) in the initial double-
blind phase of the trial, whereas in a later-open-label exten-
sion, more muscle symptoms were reported in the statin
group 1.41 (1.10–1.79).24 Interestingly, the overall rate of re-
ported muscle symptoms was lower in the open-label exten-
sion phase of the study than during the blinded phase. This
is possibly because patients who reported muscle-related
adverse effects in the ﬁrst phase were less likely to choose
to take an open-label statin than those who did not experi-
ence adverse effects. Based upon our deﬁnition, we calcu-
lated that 38% of SAMS in this study was attributable to
the drucebo effect (Tables 1 and 2).
GAUSS-3
The Goal Achievement After Utilizing an Anti-PCSK9 Antibody
in Statin Intolerant Subjects-3 (GAUSS-3) was a two-stage
RCT, which included 511 patients with intolerance to two or
more statins used in clinical treatment.30 The trial was
designed to compare the effectiveness of two non-statin
therapies (evolocumab and ezetimibe) in these patients.
Statin intolerance was conﬁrmed by a rigorous process of
crossover between blinded placebo and atorvastatin 20 mg
for up to 10 weeks to identify individuals who experienced
adverse effects while taking atorvastatin but not on
placebo.
30
In a thoughtful discussion of the data from this
phase of the study, Tobert et al. compared the rates of intol-
erable muscle-related adverse effects reported with blinded
placebo and blinded atorvastatin; 133/491 patients reported
adverse effect with both treatments or no adverse effects on
either treatment, 209/491 reported adverse events on ator-
vastatin but not placebo, and 130/491 reported adverse ef-
fects on placebo but not atorvastatin. On this basis, they
calculated that only 16% [(209–130)/491] of adverse effects
were attributable to the pharmacological effects of statins,
whereas the remaining 84% could be attributable to the
nocebo effect.2 Using our deﬁnition, we calculated that
58% of intolerable SAMS might be attributable to the
drucebo effect (Table 2).
ODYSSEY ALTERNATIVE
ODYSSEY ALTERNATIVE was another study that recruited
statin patients who had demonstrated intolerance to two
statins (one of which had to be at the lowest approved daily
starting dose) into a RCT comparing alirocumab, ezetimibe,
and atorvastatin 20 mg. Statin intolerance was conﬁrmed
by a placebo run-in and statin rechallenge arm.31 Of 361 indi-
viduals who undertook the placebo run-in, 25 (6.9%) experi-
enced skeletal muscle symptoms on placebo (nocebo
effect), and of 63 participants randomized to atorvastatin,
14 (22%) discontinued therapy because of a skeletal muscle
adverse event. This suggests that 78% of individuals who
met the criteria of statin intolerance at baseline could toler-
ate this dose of atorvastatin31 and that 78% of statin intoler-
ance may be attributed to a drucebo effect (Table 2).
Taylor et al. analysis
Taylor et al. recruited patients with a history of muscle com-
plaints into a study designed to investigate the role of coen-
zyme Q10 (CoQ10) on the frequency of statin myopathy.32
Statin myopathy was conﬁrmed in the study by a randomized
double-blind crossover treatment with placebo or simvastatin
20 mg. Treatment was for 8 weeks or until intolerable muscle
symptoms occurred, or symptoms persisted for a week.
Crossover occurred after a 4-week washout period. In this
population, statin myopathy was conﬁrmed in only 43/110
patients, indicating that for remaining 57% of patients, all
symptoms could have been attributable to the drucebo effect
(Table 2).
Joy et al. analysis
A small series of N-of-1 trials (deﬁned by the authors as single
patient, randomized, multiple crossover, blinded comparison
of active treatment vs. placebo with eight patients) was
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Table 2 Characteristics of included studies
Reference [24] [34] [32] [30] [33]
1st author Gupta Joy Moriarty Nissen Taylor
Year of publication 2017 2014 2015 2016 2015
Trial name ASCOT NA Odyssey Alternative GAUSS-3 NA
Study design Randomized, double-blind,
placebo-controlled trial
followed by open-label
statin therapy
N-of-1 trial with
three double-blind,
crossover comparisons
separated by 3-week
washout periods
Randomized, double-blind,
placebo-controlled trial
with placebo and statin
rechallenge run-in
Two-stage
randomized
clinical trial.
Initial phase
used a 24-week
crossover procedure
with atorvastatin
or placebo
Randomized
double-blind
crossover study
of statin and
placebo
Participants 10 180 8 361 511 120
Inclusion Criteria. Men and women
aged 40–79 years with
>3 risk factors for CVD
Patients aged 18 years
or older with prior
statin-related myalgia
with or without mild
elevation of CK levels
Patients aged 18 years or
older with moderate to
high cardiovascular risk
with statin intolerance
(unable to tolerate >/=2
statins, including one at
the lowest approved
starting dose)
due to muscle symptoms
Patients aged 18–80 years
with uncontrolled low
density lipoprotein
cholesterol (LDL-C)
levels and history of
intolerance to two or
more statins enrolled
Patients aged
18 years or older with
conﬁrmed
statin myalgia
Age of participants 36% ≤ 60 years
(blinded phase)
66 ± 8 63.4 ± 8.9
(atorvastatin group)
60.7 ± 10.2 (ﬁrst phase) 58 ± 11
(conﬁrmed myalgia)
34% ≤ 60 years
(blinded phase)
Mean ± SD unless
otherwise stated
58.8 ± 10.5 (second phase) 61 ± 9 (not conﬁrmed
myalgia)
Statin used Atorvastatin
10 mg daily
Atorvastatin, 10 mg daily,
Rosuvastatin, 10 mg weekly
Atorvastatin 20 mg daily Atorvastatin 20 mg daily Simvastatin 20 mg daily
Rosuvastatin, 5 mg daily
Rosuvastatin, 10 mg daily
Rosuvastatin, 20 mg daily
Pravastatin, 10 mg daily
Endpoints Annual rate of
adjudicated deﬁnite
or probable muscle
adverse effects
Visual analogue score
for myalgia, resumption
of statin treatment
Incidence of and
discontinuation due
to skeletal muscle-related
adverse events
Incidence of skeletal
muscle-related
adverse events
Incidence of muscle pain
Frequency of
intolerance/severity
of SAMS under
open-label conditions
(SAMSopen)
HR 1.41 [1.10–1.79]
vs. placebo
8 (100%) 63 (100%) 492 (100%) 120 (100%)
Explanation of how
the above was calculated
HR reported in paper Statin discontinuation
due to SAMS on open-label
therapy was inclusion
criterion for the study
Intolerance to at least 2
statins owing to SAMS
on open-label therapy
was inclusion criterion
for the study. 63/361
participants were
randomized to statin
therapy so are considered.
Intolerance to at least 2
statins owing to SAMS
on open-label therapy
was inclusion criterion
to the ﬁrst phase of the study
History of SAMS
was inclusion criteria
of the study
(Continues)
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conducted to compare the effect of statin rechallenge with
placebo in patients with previously reported muscle pain on
statin therapy.
33
The study consisted of three double-blind
crossover comparisons of the statin, which was previously
not tolerated and placebo. The primary outcome was a visual
analogue score designed to quantify myalgia. No signiﬁcant
differences in the score were found between placebo and
statin treatment phases for any of the patients. Five patients
(62.5%) resumed statin treatment (thus, 62.5% of statin
discontinuation may be attributable to a drucebo effect).
Adherence to the study protocol was extremely high, and
the authors propose their method of blinded crossover com-
parisons as an effective approach to identifying true statin-
related myalgia (Table 2).
Conclusions
Statin therapy under blinded and open-label
conditions
Our results suggest a substantial increased incidence of
statin-related muscle symptoms under open-label therapy
than when study participants are blinded to treatment. In-
deed, our estimate of the contribution of the drucebo effect
to statin-associated muscle pain and statin discontinuation
ranged between 38% and 78%. This ﬁnding reﬂects previous
observations of low rates of statin-associated myalgia in
RCTs.34 However, in many RCTs (e.g. the Treating to New
Targets trial), an open-label run-in phase was used to
eliminate patients with SAMS prior to randomization.35 The
wide range of the drucebo effect (38% and 78%) is likely to
reﬂect differences between the clinical trials employed in
our analysis. In particular, the characteristics of participants
in the trials may affect their susceptibility to the drucebo
effect. Differences in study design (in particular duration of
Table 3 Cochrane Revised Risk of Bias assessment (RoB 2.0)
Reference [24] [34] [32] [30] [33]
1st author Gupta Joy Moriarty Nissen Taylor
Year of publication 2017 2014 2015 2016 2015
Bias arising
from the
randomization
process
Low High Low Low High
Bias due to
deviations from
intended interventions
Low Low Low Low Low
Bias due to
missing outcome data
Low Low Low Low Low
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follow-up) may also contribute to the differences in results.
Further studies with both blinded and open-label phases
may allow us to reﬁne our analysis; however, it is unlikely that
there exists a ‘true’ value of the drucebo, applicable in all
circumstances. Perhaps the most important observation is
that even at the lowest estimate (38%), the drucebo effect
contributes substantially to statin discontinuation and
adverse effects.
Drucebo effect
The difference in myalgia under blinded and open-label con-
ditions corresponds to our deﬁnition of a negative drucebo
effect. The concept of ‘drucebo’ effect differs from the
‘nocebo’ effect in its practicality and in its relation to drugs
rather than inert substances. The contribution of the drucebo
effect to reported symptom worsening (or improvement) can
be estimated in any study with both blinded and open-label
phases. In contrast, accurate quantiﬁcation of the nocebo
effect requires a ‘no treatment’ group, which is very rarely
seen in clinical trials of statins. It should be emphasized that
although the drucebo effect is relatively easy to measure, it is
not a pure measure of the extent to which expectation of
symptoms leads to patients experiencing such symptoms—
because blinded patients may have expectations about the
effect of the formulation they are taking, and they may guess
its identity. Furthermore (and particularly in the case of a
relatively common symptom such as muscle pain), misattri-
bution of symptoms with other causes (such as physical
injury) as adverse drug effects will contribute to the mea-
sured drucebo effect. We have studied an example of a
‘negative’ drucebo effect; however, it is equally possible that
a patient’s expectation will lead to a beneﬁcial effect (or that
a coincidental improvement in symptoms will be incorrectly
attributed to the medicine by the patient).
Diagnosis of the drucebo effect and management of
cardiovascular risk
The contribution of the drucebo effect to any reported bene-
ﬁcial or adverse effects can be easily calculated from suitably
designed trials using the formulae deﬁned in this paper. Our
ﬁndings suggest that the prevalence of the drucebo effect
in the population is high and is responsible for a considerable
portion of statin-reported muscle pain and intolerance. How-
ever, recognizing the drucebo effect in an individual patient
requires clinical skill and discernment. It is important that
the drucebo effect is identiﬁed, because of its potential to
lead to cessation of statin therapy thus placing the patient
(especially those classiﬁed as high-risk for vascular events)
at signiﬁcantly elevated risk of heart disease, stroke, and
death.11,12 Thus, more widespread understanding of the
drucebo effect might indeed help to decrease the risk of
discontinuation and better adherence to statin therapy and
consequently may lead to a reduction in CVD events.
Identiﬁcation of the drucebo effect in an individual can be
approached largely as a diagnosis of exclusion.
• All other conditions that might increase the risk of statin
intolerance should be considered and excluded. These in-
clude drug–drug interactions, physical exertions, and
hypothyroidism.19
• Creatine kinase should be measured, because it is a reli-
able marker of true SAMS.
• The patient should be assessed using the SAMS-CI
Score8,17 to ascertain the likelihood that the muscle pain
is truly statin-related.
Patients at high risk of the drucebo effect are likely to
beneﬁt from reassurance from their prescriber and regular
follow-up. They may beneﬁt from education about the ben-
eﬁcial effects of statins in reducing CVD events and
prolonging life. It is important to understand the ‘risk
factors’, which might predispose to the drucebo effect.
Taking into account the data from the included studies,
these may include polypharmacy, age, sex, concomitant
diseases, although insufﬁcient data exist to address this
problem at present.
Use of the drucebo effect in evaluating efﬁcacy and safety of
medicines
In clinical trial designs, which allow quantiﬁcation of the
drucebo effect, useful information about the safety and efﬁ-
cacy of the treatment can be elicited by measuring adverse
effects under blinded and open-label conditions. If the inci-
dence of adverse effects in the treatment group is greater un-
der open-label conditions than when treatment allocation is
blinded (negative drucebo effect), this provides some reas-
surance that the side effects are not caused by a pharmaco-
logical action of the drug. Conversely, when reported
beneﬁts are greater under open-label conditions than when
treatment allocation is blinded (positive drucebo effect), then
caution must be employed in the interpretation of the bene-
ﬁt, and an alternative analysis using hard endpoints should be
considered. Many RCTs include placebo run-in periods prior
to randomization, and the design of such trials has allowed
us to conduct this retrospective analysis. Investigators should
consider the drucebo effect when designing studies, which
compare a treatment and a placebo, in order to improve
our understanding of this effect. If feasible and ethically
appropriate, studies should commence with run-in periods,
in which placebo and drug are crossed over in a randomized
order. Investigators should also consider including a baseline
assessment of participant expectations of experiencing ad-
verse events or side effects, which could later be compared
with incidence of adverse events during the trial.
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Limitations of the current study
Our ﬁndings in this study are based on a relatively small num-
ber of papers with a wide variety of designs, study popula-
tions, and outcome measures. This heterogeneity led us to
decide not to perform a quantitative meta-analysis at the
level of the studies. However, were it possible to perform
an individual participant data meta-analysis, it would be very
informative to stratify the analysis according to the relative
potencies of the ‘challenge’ and ‘rechallenge’ statins. The
analyses of studies we included are generally retrospective
and were often not pre-speciﬁed in the study protocols.
Some of the data we have discussed is based upon small
data sets or is from older studies in which low intensity statin
therapy is used, which is thus of limited relevance to current
therapeutic approaches. National Institute for Health and
Care Excellence recommends atorvastatin 20 mg in primary
prevention,36 whereas only two of the ﬁve studies we identi-
ﬁed used this dose,
30,31
with most participants of the remain-
ing trials taking lower intensity statin therapy. The external
validity of our study may also be reduced by the fact that
the studies eligible for inclusion in our analysis generally in-
cluded young participants (with many in their early 60s),
and therefore, the results may be less applicable to older
statin-users, who may be at particular risk of adverse effects.
The very nature and design of trials may mean that
reporting of symptoms differs from clinical practice. Tobert
and Newman, commenting upon the Heart Protection Study
(a comparison of placebo vs. simvastatin 40 mg in a mixed
high-risk population) emphasized that the incidence of mus-
cle symptoms was very high in both the placebo (33.2%)
and simvastatin-treated (32.9%) groups37 in a middle-aged
population of individuals who had been warned about
statin-associated muscle injury and were repeatedly
questioned about muscle symptoms.2 This is highly sugges-
tive of a negative drucebo effect—although direct compari-
son of rates of adverse effects in open-label and blinded
phases is not possible in this case. Tobert and Newman also
discussed the potential problems of patient unblinding in
clinical trials, which is a particular problem in crossover trials,
in which patients had access to both the placebo and active
dosage form.2 Furthermore, in studies such as GAUSS-3 and
ODYSSEY ALTERNATIVE in which patients were required to
demonstrate statin intolerance in a placebo-controlled phase
of a study before being considered for a trial of a new
therapeutic entity, the temptation for participants to be
self-unblinded may be strong.2
Our ﬁndings assume that the placebo used in the studies
was inert. Adverse effect detection was only possible during
the time course of follow-up of the individual studies. Our re-
sults may be complicated by the incidence of pain of other
causes (i.e. neither true statin-induced myalgia nor pure
nocebo effect). However, this would only be problematic if
such pain occurred at different frequencies in the different
experimental groups. Furthermore, misattribution of pain
caused by mechanical injury to statin is likely to contribute
to the drucebo effect.
We propose that the drucebo effect may prove useful in a
wide range of clinical disciplines; however, it is by no means
clear that appropriately designed trials have been carried
out in other disciplines to allow the quantiﬁcation of the
drucebo effect in other settings.
As standard practice for a systematic review, we evalu-
ated each of the studies according to the Cochrane Risk of
Bias tool. However, by necessity, all the studies we included
had non-blinded phases. Therefore, it was not possible to
use the Cochrane tool as intended. The judgments are
based only upon the blinded phase of the trials and thus
can only be used to give some indication of the quality of
the trial.
Summary and recommendations for research and
practice
The collated available evidence is suggestive of the existence
of a negative drucebo effect with respect to muscle symp-
toms on statin therapy.38 Where it can be accommodated
without prejudicing the trial, routine inclusion of unblinded
phases of clinical trials may be a useful addition to routine
practice in clinical trial design in circumstances in which
subjective endpoints are employed. Studies are urgently
needed to identify ‘risk factors’ predisposing to the
drucebo effect and to determine the prevalence of the
drucebo effect across a range of drugs and therapeutic
areas. Recent research has shown that genetic differences
between individuals can explain differing responses to pla-
cebo (the placebome concept).39 Extension of this work to
drucebo effects could provide insights into the identiﬁcation
and management of the drucebo effect in patients. It is
possible that the very extensive negative media attention
focused on the adverse effects of statins has resulted in a
particularly high prevalence of negative drucebo effects in
this setting. Clinicians should be aware of the potential of
the drucebo effect to promote treatment discontinuation.
Taking into account the best quality clinical evidence individ-
ual patient characteristics, clinicians should discuss the true
likelihood of adverse effects with patients before commenc-
ing treatment.
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